News

Cannae (NYSE:CNNE) said it returned the bulk of its first-quarter capital allocation to shareholders while continuing to evaluate sales of non-core holdings and emphasizing growth in its

• 4 Recent Earnings Winners Riding Fresh Momentum in May

SiBone (NASDAQ:SIBN) raised its full-year 2026 outlook after reporting double-digit revenue growth in the first quarter, with management

Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and

Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data

• Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30%

AST SpaceMobile (NASDAQ:ASTS) said it remains on track with its 2026 deployment and revenue plans as the satellite-to-smartphone

• 3 Reasons Analysts Love DexCom

Pediatrix Medical Group (NYSE:MD) reaffirmed its full-year 2026 adjusted EBITDA outlook after reporting what management described as a strong first quarter, supported

• Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential

RadNet (NASDAQ:RDNT) reported record first-quarter 2026 revenue and adjusted EBITDA, with management saying demand for advanced

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma

• Opal Fuels CEO on Steering the Future of Renewable Natural Gas

OPAL Fuels (NASDAQ:OPAL) said it remains on track to meet its full-year 2026 guidance despite lower first-quarter revenue and adjusted

• MarketBeat Week in Review: 12/25 - 12/29

Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain

Stratec (ETR:SBS) reported a soft start to fiscal 2026, with first-quarter revenue and adjusted earnings down from the prior-year period, but management reaffirmed its full-year guidance and said

• Former Dividend Aristocrat AT&T Posts Strong Earnings, Tries to Win Back Investors

Lumen Technologies (NYSE:LUMN) said first-quarter 2026 results were in line with its expectations as management

• What is a Value Trap? A Complete Overview

Eastman Kodak (NYSE:KODK) reported higher first-quarter revenue and operational EBITDA for 2026, with management pointing to growth in its print and

• Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors

IQVIA (NYSE:IQV) reported record first-quarter revenue and adjusted diluted earnings per share for 2026, with management citing

Haemonetics (NYSE:HAE) reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management

Globus Medical (NYSE:GMED) reported a strong start to 2026, with first-quarter revenue and earnings rising sharply as the company cited continued momentum in U.S. spine, margin expansion and

Genesis Energy (NYSE:GEL) said first-quarter 2026 results came in “a touch below” its internal expectations, primarily due to anticipated offshore producer turnarounds, lower-than-expected